Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumor lysates are more potent tumor antigens than idiotype protein to promote anti-tumor immunity
Clinical and Experimental Immunology, 07/17/2012
Hong S et al. – The study showed that tumor lysate–pulsed Dendritic cells (DCs) were more potent vaccine than the Id–pulsed DC vaccine to promote anti–tumor immunity in the model. This information will be important for improving the strategies of DC–based immunotherapy for patients with myeloma and other B–cell tumors.